MDPI and ACS Style
Shivapurkar, N.; Gay, M.D.; He, A.; Chen, W.; Golnazar, S.; Cao, H.; Duka, T.; Kallakury, B.; Vasudevan, S.; Smith, J.P.
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2023, 24, 3625.
https://doi.org/10.3390/ijms24043625
AMA Style
Shivapurkar N, Gay MD, He A, Chen W, Golnazar S, Cao H, Duka T, Kallakury B, Vasudevan S, Smith JP.
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023; 24(4):3625.
https://doi.org/10.3390/ijms24043625
Chicago/Turabian Style
Shivapurkar, Narayan, Martha D. Gay, Aiwu (Ruth) He, Wenqiang Chen, Shermineh Golnazar, Hong Cao, Tetyana Duka, Bhaskar Kallakury, Sona Vasudevan, and Jill P. Smith.
2023. "Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma" International Journal of Molecular Sciences 24, no. 4: 3625.
https://doi.org/10.3390/ijms24043625